CT-388 is a once-weekly investigational unimolecular GLP-1/GIP receptor modulator therapeutic candidate being studied in a multi-part, multi-cohort Phase 1/2 trial to assess its safety, tolerability, pharmacokinetics and pharmacodynamic effects vs. placebo in overweight and obese heathy volunteers as well as in a cohort of overweight and obese participants with type 2 diabetes. Further details about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT04838405.
CT-868 is a once-daily investigational unimolecular GLP-1/GIP receptor modulator therapeutic candidate being studied in two trials:
CT-996 is a once-daily investigational, biased, oral, small molecule GLP-1 receptor agonist being studied in a Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetic and pharmacodynamic effects in overweight/obese adults with and without type 2 diabetes.
CT-388, CT-868 and CT-996 are investigational clinical candidates.